Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NTRK1 positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH1 mutation + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

NCOR2-NTRK1 fusion + TMB-H (2)

EGFR exon 19 deletion + LMNA-NTRK1 fusion + EGFR T790M (1)

LMNA-NTRK1 fusion + NTRK1 G595R (1)

MSI-H/dMMR + NTRK1 fusion (1)

NOTCH2-NTRK1 fusion + EGFR L858R (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

TPM3-NTRK1 fusion + ALK L1196M (1)

EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH1 mutation + NTRK1 fusion (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion (2)

IDH2 mutation + NTRK1 fusion (2)

NCOR2-NTRK1 fusion + TMB-H (2)

EGFR exon 19 deletion + LMNA-NTRK1 fusion + EGFR T790M (1)

LMNA-NTRK1 fusion + NTRK1 G595R (1)

MSI-H/dMMR + NTRK1 fusion (1)

NOTCH2-NTRK1 fusion + EGFR L858R (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

TPM3-NTRK1 fusion + ALK L1196M (1)

›

NTRK1 positive	Thyroid Gland Anaplastic Carcinoma	NTRK1 positive	Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3
NTRK1 positive	Thyroid Gland Carcinoma	NTRK1 positive	Thyroid Gland Carcinoma	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3